We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

83 hedge funds and large institutions have $4.79M invested in VistaGen Therapeutics in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

1% more capital invested

Capital invested by funds: $4.75M → $4.79M (+$38.4K)

0.07% less ownership

Funds ownership: 0.66% → 0.58% (-0.07%)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

2% less funds holding

Funds holding: 85 → 83 (-2)

Holders
83
Holders Change
-2
Holders Change %
-2.35%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
24
Reduced
18
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$163K
2
State Street
State Street
Massachusetts
+$47.1K
3
Allspring Global Investments
Allspring Global Investments
North Carolina
+$37.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$36.4K
5
HNWA
Henrickson Nauta Wealth Advisors
Michigan
+$35K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$668K
2
N
Nuveen
North Carolina
-$597K
3
Two Sigma Investments
Two Sigma Investments
New York
-$57.6K
4
Citadel Advisors
Citadel Advisors
Florida
-$37K
5
Morgan Stanley
Morgan Stanley
New York
-$11.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Prudential Financial
76
Prudential Financial
New Jersey
$1.25K – – –
DWM
77
Drive Wealth Management
Utah
$1.25K – – –
Simplex Trading
78
Simplex Trading
Illinois
$1K -$4.74K -903 -65%
Royal Bank of Canada
79
Royal Bank of Canada
Ontario, Canada
$1K -$2.97K -566 -59%
Russell Investments Group
80
Russell Investments Group
United Kingdom
$112 +$157 +30 New
Citigroup
81
Citigroup
New York
$19 -$246 -47 -90%
Commonwealth Equity Services
82
Commonwealth Equity Services
Massachusetts
$2 +$173 +33 +5%
N
83
Nuveen
North Carolina
– -$597K -18,587 Closed
Millennium Management
84
Millennium Management
New York
– -$11K -3,583 Closed
Renaissance Technologies
85
Renaissance Technologies
New York
– -$11K -3,493 Closed
ETC
86
Exchange Traded Concepts
Oklahoma
– -$8.57K -2,774 Closed
Balyasny Asset Management
87
Balyasny Asset Management
Illinois
– -$8.42K -2,726 Closed
Two Sigma Advisers
88
Two Sigma Advisers
New York
– -$3.45K -1,117 Closed
LPL Financial
89
LPL Financial
California
– -$3.3K -1,067 Closed
AQR Capital Management
90
AQR Capital Management
Connecticut
– -$1.07K -346 Closed
AWS
91
Atria Wealth Solutions
New York
– -$1.03K -333 Closed
Belvedere Trading
92
Belvedere Trading
Illinois
– -$511 -165 Closed
IA
93
IFP Advisors
Florida
– -$5K -114 Closed
EI
94
Ellevest Inc
New York
– -$33 -11 Closed
CS
95
Credit Suisse
Switzerland
– -$1 – –
1 2 3
4

VTGN Hedge Fund Activity: Q1 2023 in Review

83 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2023, worth a combined $4.79M — up 0.81% from $4.75M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of VTGN and 12 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 24 added.

The largest buyer was BlackRock, adding an estimated $163K. The largest seller was GSA Capital Partners, cutting an estimated $668K.

  • 83 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2023, down from 85 in Q4 2022.
  • Funds reported $4.79M of VistaGen Therapeutics stock for Q1 2023, up 0.81% quarter-over-quarter.
  • 12 funds opened new VistaGen Therapeutics positions in Q1 2023 and 13 closed out, a net change of -1 holder.
  • The largest VistaGen Therapeutics buyer in Q1 2023 was BlackRock, an estimated $163K added.
  • The largest VistaGen Therapeutics seller in Q1 2023 was GSA Capital Partners, an estimated $668K sold.

Based on aggregated 13F filings for Q1 2023.